Almac Clinical Technologies announces expedited support for COVID-19 Clinical Trials

Expedited implementation of Interactive Response Technology (IRT) in support of pandemic research efforts

Souderton, PA, USA, 7 Apr 2020 – Almac Clinical Technologies, a member of the Almac Group, has today announced the expedited deployment and support of multiple Interactive Response Technology (IRT) solutions in support of COVID-19 treatments.

Several clinical trial sponsors have recently entrusted Almac in order to support expedited pathways to emergency clinical trials designed to investigate the efficacy of investigational medicinal products and commercially pre-approved medicinal products to reduce the impact of the novel COVID-19 coronavirus.

The result of these collaborations materialized in the form of fully-functioning IRT systems  used for patient randomization and clinical trial material management that were designed, validated, and deployed in as little as one week.

As part of Almac’s ongoing commitment to innovation and providing a better IRT experience for clinical trial operations, a novel, expedited process was utilized to reduce the time requirements and input needed from trial sponsors – thereby ensuring the focus could remain on optimizing patient outcomes.

In one instance, the date for the first patient to be enrolled shifted, and Almac had to deliver the IRT system a day earlier than what had been initially planned. The client’s request was circulated among Almac teams on a Friday afternoon, and by Saturday, an array of IRT specialists had already established how they could deliver for the sponsor. The Almac team volunteered to work tirelessly on nights and weekends to be part of what they hope may lead to a scientific breakthrough.

Valarie Higgins, President and Managing Director, Almac Clinical Technologies commented: “In times such as these, Almac’s mission to Advance Human Health has never been more applicable. We stand committed in global solidarity – to do our part in reducing the burden and barriers involved in solving global challenges such as COVID-19 through clinical research. We hope to that our singular focus on the rapid delivery and support of Interactive Response Technology used in clinical trials will prove to be a catalyst in advancing the research and data acquisition efforts that are urgently needed. We stand ready and committed to supporting our biopharmaceutical partners through any means necessary.”

To find out more about Almac, visit here.

ENDS

About Almac Group

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.

To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.